Allergy Therapeutics plc announced the appointments of Anthony Parker and Zheqing (Simon) Shen as Non-Executive Directors of the company, with immediate effect. Anthony represents Southern Fox Investments Limited and Simon represents ZQ Capital Management Limited acting through its affiliate SkyGem Acquisition Limited, both significant shareholders of the company. Anthony has worked in investment banking and fund management for over thirty years and, as Founder and Partner of Beagle Partners LLP, which advises Southern Fox, has managed or advised on multiple UK innovation technology investments. He is Founder and Chairman of Argonaute RNA Ltd, a UK-based research company developing safe and reliable methods of temporarily silencing target genes in different tissue cells. Prior to this, Anthony held senior roles at ING Barings and was an equity analyst for Cazenove & Co. He holds an Investment Management Certificate from the Institute of Investment Management and Research. Simon founded the investment and advisory firm, ZQ Capital, in 2015. Prior to that he spent more than a decade as an investment banker advising international companies on their capital markets activities. He was Managing Director and Head of China Financial Institutions Group at Barclays from 2011 to 2015, following earlier roles at Goldman Sachs, Lehman Brothers and McKinsey & Company. He has a BA in mathematics and economics from Wesleyan University. Mr. Anthony Michael Parker (aged 60)'s current Directorships and Partnerships: Argonaute RNA Limited, Bristol Bluegreen Limited, Beagle Partners LLP,
CBDerma Technology Limited, Inverpharma Limited and Las Lilas Limited. Mr. Zheqing (Simon) Shen (aged 43)'s Current Directorships and Partnerships: ECC HK Holdings Limited, Fortune Yacht Limited, KFM Kingdom Holdings Limited, Nu Skin Enterprises Inc., Ping An ZQ China Growth Opportunity Ltd, Sky Venture Partners LP, Skygem Acquisition Limited, Skygem Global Limited, Skygem International Holdings Limited, Skygem Investment Limited, Skygem UK Holding Limited, ZQ Asset Management Limited, ZQ Capital Hong Kong Holdings Ltd, ZQ Capital Hong Kong Limited, ZQ Capital Limited, ZQ Capital Management Limited, ZQ Capital Services Limited, ZQ Evergreen Partners LP, ZQ Partners Ltd, ZQ Skygem Investors LP and Z-Trans Technology Company Limited.